Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wassim Abida

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|March 20, 2025
State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate CancerWassim Abida, Himisha Beltran, Ruben Raychaudhuri
Hematology/Oncology Clinics of North America|April 4, 2015
First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patientsWassim Abida, Dean F Bajorin, Jonathan E Rosenberg
Current Oncology (Toronto, Ont.)|June 23, 2022
A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a <i>RAD51B Alteration</i>Brieuc Sautois, Andrea Loehr, Simon P Watkins, et al.
Cancer Management and Research|February 25, 2022
Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate CancerBrian W Labadie, David S Morris, Alan H Bryce, et al.
European Urology Oncology|December 5, 2024
Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate CancerFrancesca Zacchi, Wassim Abida, Emmanuel S Antonarakis, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 4, 2019
Low Expression of the Androgen-Induced Tumor Suppressor Gene <i>PLZF</i> and Lethal Prostate CancerKonrad H Stopsack, Travis Gerke, Svitlana Tyekucheva, et al.
The Prostate|September 20, 2017
Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy MeetingAndrea K Miyahira, Heather H Cheng, Wassim Abida, et al.
Prostate Cancer and Prostatic Diseases|September 27, 2024
Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)Anthony V Serritella, Amy Taylor, Michael C Haffner, et al.
Prostate Cancer and Prostatic Diseases|October 1, 2024
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)Andrew J Armstrong, Amy Taylor, Michael C Haffner, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial CarcinomaWassim Abida, Matthew I Milowsky, Irina Ostrovnaya, et al.
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|March 20, 2025
State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate CancerWassim Abida, Himisha Beltran, Ruben Raychaudhuri
Hematology/Oncology Clinics of North America|April 4, 2015
First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patientsWassim Abida, Dean F Bajorin, Jonathan E Rosenberg
Current Oncology (Toronto, Ont.)|June 23, 2022
A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a <i>RAD51B Alteration</i>Brieuc Sautois, Andrea Loehr, Simon P Watkins, et al.
Cancer Management and Research|February 25, 2022
Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate CancerBrian W Labadie, David S Morris, Alan H Bryce, et al.
European Urology Oncology|December 5, 2024
Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate CancerFrancesca Zacchi, Wassim Abida, Emmanuel S Antonarakis, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 4, 2019
Low Expression of the Androgen-Induced Tumor Suppressor Gene <i>PLZF</i> and Lethal Prostate CancerKonrad H Stopsack, Travis Gerke, Svitlana Tyekucheva, et al.
The Prostate|September 20, 2017
Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy MeetingAndrea K Miyahira, Heather H Cheng, Wassim Abida, et al.
Prostate Cancer and Prostatic Diseases|September 27, 2024
Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)Anthony V Serritella, Amy Taylor, Michael C Haffner, et al.
Prostate Cancer and Prostatic Diseases|October 1, 2024
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)Andrew J Armstrong, Amy Taylor, Michael C Haffner, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial CarcinomaWassim Abida, Matthew I Milowsky, Irina Ostrovnaya, et al.
Pageof 9